Shawwhitney4368
We evaluated the effect of the latest GLP-1 RA semaglutide on tongue fat storage in obese women.
We conducted a randomized single-blind, pilot study.
Twenty-five obese women with polycystic ovary syndrome (PCOS) (33.7±5.3years, body mass index (BMI) 36.1±3.9kg/m2, mean±SD) were randomized to semaglutide 1.0mg or placebo for 16weeks. We quantified tongue volume and its fat tissue and fat proportion by magnetic resonance imaging.
Tongue fat tissue and fat proportion significantly reduced after semaglutide vs placebo (-1.94±5.51 vs.+3.12±4.87cm
, p=0.022, and -0.02±0.07 vs. 0.04±0.06, p=0.010, respectively). Correlation analysis revealed that these reductions were associated with those in body weight, BMI and waist circumference (p=0.010 for all).
This is the first study confirming the beneficial effect of semaglutide on tongue structure in obese women with PCOS. Further studies are needed to assess the clinical importance of such findings.
This is the first study confirming the beneficial effect of semaglutide on tongue structure in obese women with PCOS. Further studies are needed to assess the clinical importance of such findings.
SURE Switzerland (NCT03631186) investigated real-world once-weekly (OW) semaglutide use in adults with type 2 diabetes (T2D).
This multicentre, prospective, observational study enrolled adults with T2D with≥1 documented HbA
value≤12weeks before semaglutide initiation. this website Primary endpoint was change in HbA
from baseline to end of study (EOS; ~30weeks). Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA
<8.0%, <7.5% and <7.0% at EOS. Semaglutide dose at EOS was a prespecified exploratory endpoint.
Overall, 214 patients initiated semaglutide (baseline HbA
7.8% [62mmol/mol], BW 99.9kg and WC 117.4cm); 187 attended the EOS visit. At EOS, 175 (81.8%) were still receiving semaglutide (mean [SD] dose 0.78 [0.29] mg); in those patients, mean HbA
reduced by -0.8 [95% CI-1.01;-0.68] %-points (-9 [-11;-7] mmol/mol), BW by -5.0kg [-5.73;-4.24] and WC by -4.8cm [-5.75;-3.79] (all p<0.0001). At EOS, 85.9%, 76.5% and 55.9% patients achieved, respectively, HbA
<8.0%, <7.5% and<7.0%. No new safety signals were identified.
Patients with T2D in Switzerland initiating OW semaglutide experienced clinically relevant glycaemic control and BW improvements in a real-world setting, supporting semaglutide use in routine clinical practice.
Patients with T2D in Switzerland initiating OW semaglutide experienced clinically relevant glycaemic control and BW improvements in a real-world setting, supporting semaglutide use in routine clinical practice.
The mixed meal tolerance test (MMTT) is a gold standard for evaluating beta-cell function. There is limited data on MMTT in monogenic diabetes (MD). Therefore, we aimed to analyze plasma C-peptide (CP) kinetics during MMTT in young MODY and neonatal diabetes patients as a biomarker for beta-cell function.
We included 41 patients with MD diagnosis (22 GCK, 8 HNF1A, 3 HNF4A, 4 KCNJ11, 2 ABCC8, 1 INS, 1 KLF11). Standardized 3-hour MMTT with glycemia and plasma CP measurements were performed for all individuals. Pancreatic beta-cell response was assessed by the area under the curve CP (AUC
), the baseline CP (CP
) and the peak CP (CP
). Threshold points of CP
, CP
, CP
and CP
were determined from analysis of ROC curves.
GCK diabetes patients had significantly higher AUC
, CP
and CP
compared to HNF4A and KCNJ11 patients. In HNF4A, KCNJ11 and ABCC8 patients with all CP levels<200pmol/L, the treatment change attempt to sulfonylurea agent was unsuccessful. The ROC analysis showed that CP baseline threshold equal or higher to 133.5pmol/L could be used to predict successful switch to oral agents.
A pretreatment challenge with MMTT might be used to guide the optimal treatment after molecular diagnosis of MD.
A pretreatment challenge with MMTT might be used to guide the optimal treatment after molecular diagnosis of MD.The coronavirus disease 19 (COVID-19) has turned out to be a pandemic in short period of time due to the high transmissibility of its causative agent, severe acute respiratory syndrome coronavirus 2. Various reports have suggested the promising link between overexpression of angiotensin converting enzyme 2 (ACE2) and COVID-19 pathogenesis. The severity of COVID-19 pathophysiology is greatly depended on several comorbidities, like hypertension, diabetes mellitus (DM), respiratory and cardiovascular disease, out of which DM has emerged as a major risk factor. The current review focuses on the link among the expression of ACE2, use of ACE inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), and risk of COVID-19 pathogenesis in DM. The review also emphasizes on synergistic detrimental effect of DM and COVID-19 on the immune system in provoking uncontrolled cytokine storm which eventually leads to lethal consequences. Finally, several possible therapeutic strategies have been highlighted to reduce the excess of risk associated with COVID-19 in people with DM.
To examine the association of physical activity (PA) and sedentary time (ST) with glucose metabolism according to waist circumference (WC) in older people.
A population-based sample of 702 individuals (aged 67-70years) wore wrist-worn accelerometers for two weeks and underwent an oral glucose tolerance test. The associations between moderate-to-vigorous (MVPA) and light (LPA) PA, ST, and glucose metabolism across the tertiles of WC were analysed using general linear regression.
Among highest WC tertile, LPA negatively associated with fasting insulin (β=-0.047, 95% CI-0.082 to-0.012), HOMA-IR (β=-0.098, 95% CI-0.184 to-0.012), and HOMA-β (β=-3.367, CI-6.570 to-0.783). ST associated with 120min glucose (β=0.140, CI 0.021 to 0.260). Among lowest WC tertile, MVPA negatively associated with 30min insulin (β=-0.086, 95% CI-0.168 to-0.004) and 120min insulin (β=-0.160, 95% CI-0.257 to-0.063) and positively associated with Matsuda index (β=0.076, 95% CI 0.014 to 0.139). Light PA negatively associated with 120min insulin (β=-0.